PlexBio CoROCO:6572 67 EBITDA Margin % is -15.33% as of Dec. 2025. GuruFocus rates ROCO:6572 with a GF Score™ of 67/100 and a GF Value™ of NT$9.52 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, PlexBio Co ranks worse than 75.89% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PlexBio Co's EBITDA for the
six
months ended in Dec. 2025 was NT$-10.6 Mil. PlexBio Co's Revenue for the
six
months ended in Dec. 2025 was NT$68.8 Mil. Therefore, PlexBio Co's EBITDA margin for the quarter that ended in Dec. 2025 was -15.33%.
PlexBio Co (ROCO:6572) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PlexBio Co EBITDA Margin % Related Terms
PlexBio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PlexBio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6572 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, PlexBio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PlexBio Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PlexBio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PlexBio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PlexBio Co (ROCO:6572) has a EBITDA Margin % of -15.33% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PlexBio Co and its competitors. According to the industry distribution chart, PlexBio Co ranks #620 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 75.9%.
Is PlexBio Co's EBITDA Margin % too high?
PlexBio Co's current EBITDA Margin % is -15.33%. Based on the distribution chart, PlexBio Co ranks #620 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PlexBio Co has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PlexBio Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, PlexBio Co ranks #620 out of 817 companies for EBITDA Margin %. This places PlexBio Co in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PlexBio Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PlexBio Co's current EBITDA Margin % is -15.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PlexBio Co stock overvalued right now?
Based on GuruFocus' analysis, PlexBio Co (ROCO:6572) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$9.52, compared to a current price of NT$7.62 — trading 20% below its estimated fair value. The current EBITDA Margin % is -15.33%. PlexBio Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PlexBio Co (ROCO:6572), the current EBITDA Margin % is -15.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PlexBio Co (ROCO:6572) Overvalued in 2026?
Based on GuruFocus' analysis, PlexBio Co stock appears to be undervalued.
The current stock price of NT$7.62 is trading 20% below its estimated GF Value™ of NT$9.52.
GuruFocus considers PlexBio Co to be Modestly Undervalued.
Key valuation signals for ROCO:6572:
EBITDA Margin %: -15.33%
GF Value™: NT$9.52 vs. price of NT$7.62 (20% below fair value)
No single metric tells the full story. See the ROCO:6572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PlexBio Co Ltd is a Taiwan based company involved in designing, developing and manufacturing IVD products and instrumentations. Its products are used in companion diagnostic panel, early cancer detection screening, prenatal diagnostics and for food and safety testing.
67GF Score
Get the complete analysis for ROCO:6572
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6572 has been successfully added to your 
